Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti, selettiv immunosuppressanti - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - aġenti antineoplastiċi - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - limfoma, mantle-cell - inibituri tal-proteina kinase - treatment of mantle cell lymphoma (mcl).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - zytiga huwa indikat ma 'prednisone jew prednisolone: - trattament tal-kanċer metastatiku tal-kastrazzjoni reżistenti għall-kanċer tal-prostata fl-irġiel adulti li huma asintomatiċi jew ħafif sintomatika wara l-falliment tat-terapija tal-privazzjoni tal-androgen fil-għalihom kimoterapija għadu mhux klinikament indicatedthe-trattament tal-kanċer metastatiku tal-kastrazzjoni reżistenti għall-kanċer tal-prostata fl-irġiel adulti li l-marda tagħhom mexa fuq jew wara docetaxel kimoterapija bbażata fuq il-kors ta'.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanedjol monohydrate - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogi użati fid-dijabete - qtern, taħlita fissa tad-doża ta saxagliptin u dapagliflozin, huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta metformin u/jew mediċina tat-tip sulphonylurea (su) u waħda mill-monokomponenti tal-qtern ma jipprovdux kontroll gliċemiku adegwat,meta diġà qegħdin jiġu ttrattati bil-kombinazzjoni ħielsa ta dapagliflozin u saxagliptin. (ara sezzjonijiet 4. 2, 4. 4, 4. 5 u 5. 1 għall-dejta disponibbli dwar il-kombinazzjonijiet studjat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - pressjoni għolja - sistema kardjovaskulari - rasitrio huwa indikat għall-kura ta ' l-ipertensjoni essenzjali bħala terapija ta ' sostituzzjoni fil-pazjenti adulti l-pressjoni tad-demm tagħhom huwa kontrollat adegwatament dwar il-kombinazzjoni ta ' aliskiren, amlodipine u idrochlorothiazide mogħtija fl-istess ħin fl-istess doża livell bħal fl-għaqda.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetate - neoplasmi prostatiċi - terapija endokrinali - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.